Browse grants
Federal and state grant opportunities with plain-English eligibility summaries. We aggregate public records — always verify the details on the funder’s site before applying. Or browse the complete index →
Catalyze Product Definition Medical Device prototype design/testing and disease target identification and assay development (R61/R33 - Clinical Trial Not Allowed)
Due Dec 23, 2027National Institutes of Health · Amount varies
This NHLBI Catalyze (R61/R33) phased opportunity funds medical device prototype design and testing, disease-target identification, and assay development for heart, lung, blood, and sleep diseases. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.
ResearchersSchools & universitiesNarrow eligibilityCatalyze: Product Definition Medical Device Prototype Optimization (R33 - Clinical Trial Not Allowed)
Due Dec 23, 2027National Institutes of Health · Amount varies
This NHLBI Catalyze (R33) opportunity funds early-stage translational work to optimize medical device prototypes, develop diagnostic assays, and create research tools for heart, lung, blood, and sleep diseases. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.
ResearchersSchools & universitiesNarrow eligibilityCatalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
Due Dec 23, 2027National Institutes of Health · Up to $350K
This NHLBI Catalyze (R33) opportunity funds rigorous validation of transformative, multi-use platforms or technologies that can advance detection, diagnosis, treatment, or prevention of heart, lung, blood, and sleep diseases. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. The maximum award is about $350,000.
ResearchersSchools & universitiesNarrow eligibilityCatalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)
Due Dec 23, 2027National Institutes of Health · Amount varies
This NHLBI Catalyze (R61/R33) phased opportunity funds target identification and validation plus preliminary product or lead-series identification for small molecules, biologics, and combination products treating heart, lung, blood, and sleep diseases. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.
ResearchersSchools & universitiesNarrow eligibilityCatalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed)
Due Dec 23, 2027National Institutes of Health · Amount varies
This NHLBI Catalyze (R33) opportunity funds early-stage translational work to identify and characterize therapeutic candidates and combination products (small molecules and biologics) for heart, lung, blood, and sleep diseases. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.
ResearchersSchools & universitiesNarrow eligibilityCONTAMINATED ALASKA NATIVE CLAIMS SETTLEMENT ACT LANDS ASSISTANCE PROGRAM
Due Dec 31, 2027Environmental Protection Agency · Up to $3M
This EPA program funds assessment and remediation of contaminated Alaska Native Claims Settlement Act lands, plus related community outreach. Eligibility is limited to Alaska Native regional and village corporations, federally recognized Tribes in Alaska, Alaska Native nonprofit associations, and inter-tribal consortia of Alaskan tribal entities. The maximum award is up to about $3,000,000, and proposals are accepted on a rolling basis; applicants are asked to contact program managers first.
Government / tribalNonprofitsLarge awardNarrow eligibilityNPS Cooperative Ecosystems Studies Units (CESU) Master Cooperative Agreements
Due Dec 31, 2027National Park Service · Amount varies
This National Park Service opportunity offers Master Cooperative Agreements to participants in the Cooperative Ecosystem Studies Units (CESU) network across listed regions, supporting research, technical assistance, education, and capacity building. Only existing CESU network partners may apply, so applicants must already have joined the network. No specific award amount is provided.
ResearchersSchools & universitiesGovernment / tribalNarrow eligibilityNIDCR Drug, Biologic, Device and/or Procedure Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
Due Jan 6, 2028National Institutes of Health · Amount varies
This NIDCR (UG3/UH3) cooperative agreement funds planning and implementation of drug, biologic, device, or procedure intervention clinical trials within NIDCR's mission. A clinical trial is required. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.
ResearchersSchools & universitiesNarrow eligibilityStimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)
Due Jan 6, 2028National Institutes of Health · Amount varies
This NIH SHINE (R01) opportunity supports innovative basic and early translational research in nonmalignant hematology, relevant to NIDDK, NIA, and NHLBI missions. It is intended for research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.
ResearchersSchools & universitiesNarrow eligibilityContinuation or Revision of NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UH3 Clinical Trial Required)
Due Jan 6, 2028National Institutes of Health · Amount varies
This NIDCR (UH3) opportunity funds competing renewal or competitive revision of ongoing clinical trials already supported by NIDCR; a clinical trial is required. Because it continues existing NIDCR-funded trials, it is effectively limited to current grantees and not open to new projects. It is aimed at research and academic institutions; foreign organizations are not eligible. No specific award amount is stated.
ResearchersSchools & universitiesNarrow eligibilityNIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
Due Jan 6, 2028National Institutes of Health · Up to $500K
This NIDCR (UG3/UH3) cooperative agreement funds planning and implementation of behavioral and social intervention clinical trials for dental, oral, or craniofacial conditions, with a milestone-driven planning phase before transition to a full trial. A clinical trial is required. It is aimed at research and academic institutions; foreign organizations are not eligible. The maximum award is about $500,000.
ResearchersSchools & universitiesLarge awardNarrow eligibilityDevelopment of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed)
Due Jan 7, 2028National Institutes of Health · Up to $200K
This NIH ORIP (R21) opportunity funds research to develop, improve, and preserve animal models and related biological materials with broad applicability across multiple NIH institutes; single-disease or single-institute projects are out of scope. It is aimed at research and academic institutions; foreign organizations are not eligible. The maximum award is about $200,000.
ResearchersSchools & universitiesNarrow eligibilityDevelopment of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional)
Due Jan 7, 2028National Institutes of Health · Amount varies
This NIH (R61/R33) opportunity funds discovery and early evaluation of candidate biomarkers for neurological and neuromuscular disorders, requiring preliminary human-sample evaluation. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.
ResearchersSchools & universitiesNarrow eligibilityMechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)
Due Jan 7, 2028National Institutes of Health · Up to $500K
This NCI (R01) opportunity funds investigator-initiated studies on the mechanisms by which bariatric surgery affects cancer risk. It is intended for research and academic institutions; foreign organizations are not eligible to apply. The maximum award is about $500,000.
ResearchersSchools & universitiesLarge awardNarrow eligibilityFocused Technology Research and Development (R01 Clinical Trial Not Allowed)
Due Jan 7, 2028National Institutes of Health · Amount varies
This NIH award funds research projects developing new technologies to advance biomedical knowledge acquisition, aimed at institutions including HBCUs, Hispanic-serving institutions, and tribal colleges, among others. Foreign organizations and their non-U.S. components are not eligible to apply. No specific dollar amount is listed, and the deadline is not imminent.
Schools & universitiesResearchersNarrow eligibilityMolecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)
Due Jan 7, 2028National Institutes of Health · Up to $500K
This NIH (R01) opportunity funds development and use of molecular imaging methods to study inflammation in cancer in vivo, encouraging collaboration between cancer biologists and imaging scientists. It is intended for research and academic institutions; foreign organizations are not eligible to apply. The maximum award is about $500,000.
ResearchersSchools & universitiesLarge awardNarrow eligibilityMood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)
Due Jan 7, 2028National Institutes of Health · Amount varies
This NIH (R21) opportunity funds translational research into mood and psychosis symptoms during the menopause transition, examining underlying neurobiological and behavioral mechanisms. It targets research and academic institutions and interdisciplinary research teams, not individuals or typical nonprofits/small businesses. No specific award amount is stated.
ResearchersSchools & universitiesNarrow eligibilityNIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Clinical Trial Not Allowed)
Due Jan 7, 2028National Institutes of Health · Amount varies
This NIDCR (K22) career-transition award helps qualified dentists move from NIH intramural postdoctoral positions to extramural faculty roles, funding mentored training plus independent research. It is an individual career-development award for early-career dentist-scientists at eligible institutions; foreign organizations are not eligible. This is narrowly targeted and not suited to organizations seeking project funding. No specific award amount is stated.
ResearchersSchools & universitiesNarrow eligibilityResearch Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed)
Due Jan 7, 2028National Institutes of Health · Up to $375K
The REAP program funds small-scale research at health professional and graduate schools that haven't been major recipients of NIH support, while giving students hands-on research experience. Eligibility is limited to institutions awarding NIH-relevant degrees that received under $6 million per year in NIH support in 4 of the last 7 years — a specific financial threshold worth checking before applying. Awards go up to $375,000.
ResearchersSchools & universitiesNarrow eligibilityIntegration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)
Due Jan 7, 2028National Institutes of Health · Up to $500K
An NIH/NCI research project grant (R01) funding projects that integrate medical imaging with fluid-based (liquid biopsy) tumor monitoring during cancer therapy. Eligible applicants are domestic institutions such as universities, tribal governments, and community-based organizations; foreign organizations and foreign components are not eligible. The award is capped at about $500,000. This is an oncology research mechanism aimed at research institutions, not individuals or general nonprofits.
ResearchersSchools & universitiesGovernment / tribalNonprofits+2 more